STIM — Neuronetics, Inc.

Neuronetics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $37.3 million, up 101% year-over-year, primarily due to the Greenbrook acquisition. On a pro forma basis, revenue increased by 11%.
• NeuroStar Revenue: $15.5 million, down 4% on a pro forma basis, attributed to changes in customer purchasing patterns.
• Gross Margin: 45.9%, significantly down from 75.6% in the previous year, largely due to the lower-margin Greenbrook clinic operations.
• Operating Expenses: $24.4 million, a 12% increase from $21.7 million in Q3 2024.
• Net Loss: $9.4 million ($0.13 per share), improved from a net loss of $13.3 million ($0.44 per share) in the prior year.
• EBITDA: Negative $6.4 million, an improvement from negative $11.6 million year-over-year.
• Cash Position: $34.5 million as of September 30, 2025, including $28 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Integration and Growth: Successful integration of Greenbrook clinics, with a 25% revenue increase in this segment.
• SPRAVATO Rollout: 84 out of 89 eligible clinics now offering SPRAVATO, with a focus on optimizing billing methods to enhance profitability.
• Better Me Provider Program: Nearly 425 active sites, contributing to increased patient treatment rates.
• Operational Efficiencies: Introduction of self-check-in kiosks and automation in patient intake processes to enhance operational efficiency and patient experience.
• New Partnerships: Secured a 3-year agreement with Elite DNA Behavioral Health to provide TMS systems and expanded collaboration with Transformations Care Network.

3. Forward Guidance and Outlook

• Q4 Revenue Guidance: Expected between $40 million and $43 million; full-year 2025 revenue projected at $147 million to $150 million, revised down from previous guidance.
• Gross Margin Expectation: Full-year gross margin expected to be between 47% and 49%, down from prior guidance of 48% to 50%.
• Operating Cash Flow: Targeting positive cash flow from operations in Q4, with a projected range of $2 million positive to $2 million negative.

4. Bad News, Challenges, or Points of Concern

• Declining NeuroStar Treatment Session Revenue: Despite increased utilization, treatment session revenue was down year-over-year due to inventory adjustments and purchasing patterns.
• Gross Margin Compression: Significant decline in gross margin due to the integration of lower-margin Greenbrook operations and changes in revenue mix.
• SPRAVATO Billing Dynamics: Ongoing adjustments in the mix of A&O versus Buy & Bill billing methods could impact revenue predictability.
• Management Transition: CEO Keith Sullivan announced plans to retire in June 2026, which may raise concerns about leadership continuity.

5. Notable Q&A Insights

• Growth Dynamics: Greenbrook clinics are driving strong growth, while NeuroStar's revenue is affected by inventory management from last year.
• Operational Efficiencies: Management is optimistic about future cost reductions and operational efficiencies, though some investments will be necessary in the short term.
• Provider Connection Program: This initiative is showing positive results, particularly in increasing referrals from primary care physicians for both NeuroStar and Greenbrook clinics.
• Adolescent Indication: There is a noted uptick in adolescent patient starts, driven by increased awareness among primary care providers.

This summary encapsulates the key points from Neuronetics' Q3 2025 earnings call, highlighting both the achievements and challenges faced by the company.